HMGB1: A Possible Crucial Therapeutic Target for COVID-19?
作者信息
Street Maria Elisabeth
机构信息
Division of Paediatric Endocrinology and Diabetology and Research Laboratory, Department of Mother and Child, Paediatrics, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy,
出版信息
Horm Res Paediatr. 2020;93(2):73-75. doi: 10.1159/000508291. Epub 2020 May 6.
Abstract
摘要
相似文献
1
HMGB1: A Possible Crucial Therapeutic Target for COVID-19?高迁移率族蛋白B1：新冠病毒病一个可能的关键治疗靶点？
Horm Res Paediatr. 2020;93(2):73-75. doi: 10.1159/000508291. Epub 2020 May 6.
2
Convalescent donor SARS-COV-2-specific cytotoxic T lymphocyte infusion as a possible treatment option for COVID-19 patients with severe disease has not received enough attention till date.恢复期供体的新冠病毒特异性细胞毒性T淋巴细胞输注作为重症COVID-19患者的一种可能治疗选择，迄今为止尚未得到足够关注。
Br J Haematol. 2020 Jun;189(6):1062-1063. doi: 10.1111/bjh.16780. Epub 2020 May 19.
3
Cell-Free Therapies: Novel Approaches for COVID-19.无细胞疗法：治疗新冠肺炎的新方法。
Front Immunol. 2020 Sep 18;11:583017. doi: 10.3389/fimmu.2020.583017. eCollection 2020.
4
Obesity, COVID-19 and immunotherapy: the complex relationship!肥胖、新冠病毒病与免疫疗法：复杂的关系！
Immunotherapy. 2020 Oct;12(15):1105-1109. doi: 10.2217/imt-2020-0178. Epub 2020 Jul 17.
5
SARS-CoV-2: a new aetiology for atypical lymphocytes.严重急性呼吸综合征冠状病毒2型：非典型淋巴细胞的一种新病因。
Br J Haematol. 2020 Jun;189(5):845. doi: 10.1111/bjh.16730. Epub 2020 May 14.
6
Dysregulated adaptive immune response contributes to severe COVID-19.适应性免疫反应失调会导致重症 COVID-19。
Cell Res. 2020 Sep;30(9):814-816. doi: 10.1038/s41422-020-0391-9. Epub 2020 Aug 5.
7
Coronavirus Disease 2019 (COVID-19) and Immune-Engaging Cancer Treatment.2019冠状病毒病（COVID-19）与免疫参与性癌症治疗
JAMA Oncol. 2020 Oct 1;6(10):1529-1530. doi: 10.1001/jamaoncol.2020.2367.
8
Reactive lymphocytes in patients with COVID-19.新型冠状病毒肺炎患者中的反应性淋巴细胞
Br J Haematol. 2020 Jun;189(5):844. doi: 10.1111/bjh.16690. Epub 2020 May 5.
9
COVID-19 and post-traumatic stress disorder: A vicious circle involving immunosuppression.新冠病毒病与创伤后应激障碍：一个涉及免疫抑制的恶性循环。
CNS Neurosci Ther. 2020 Aug;26(8):876-878. doi: 10.1111/cns.13431.
10
Optimizing Administration of CAR T-Cell Therapy During the COVID-19 Pandemic.在2019冠状病毒病大流行期间优化嵌合抗原受体T细胞疗法的给药
Clin Adv Hematol Oncol. 2020 Jul;18(7):400-403.
引用本文的文献
1
Immuno-Microbial Signature of Vaccine-Induced Immunity against SARS-CoV-2.疫苗诱导的抗SARS-CoV-2免疫的免疫微生物特征
Vaccines (Basel). 2024 Jun 7;12(6):637. doi: 10.3390/vaccines12060637.
2
The association between high mobility group box 1 (HMGB1) and Interleukin-18 (IL-18) serum concentrations in COVID-19 inpatients.新冠病毒肺炎住院患者血清中高迁移率族蛋白B1（HMGB1）与白细胞介素-18（IL-18）浓度之间的关联
Heliyon. 2024 Feb 20;10(5):e26619. doi: 10.1016/j.heliyon.2024.e26619. eCollection 2024 Mar 15.
3
Serum High-Mobility Group Box 1 and Heme Oxygenase-1 as Biomarkers in COVID-19 Patients at Hospital Admission.血清高迁移率族蛋白 1 和血红素加氧酶-1 作为 COVID-19 患者入院时的生物标志物。
Int J Mol Sci. 2023 Aug 24;24(17):13164. doi: 10.3390/ijms241713164.
4
Potential treatments of COVID-19: Drug repurposing and therapeutic interventions.COVID-19 的潜在治疗方法：药物再利用和治疗干预。
J Pharmacol Sci. 2023 May;152(1):1-21. doi: 10.1016/j.jphs.2023.02.004. Epub 2023 Feb 15.
5
The role of HMGB1 in COVID-19-induced cytokine storm and its potential therapeutic targets: A review.HMGB1 在 COVID-19 诱导的细胞因子风暴中的作用及其潜在的治疗靶点：综述。
Immunology. 2023 Jun;169(2):117-131. doi: 10.1111/imm.13623. Epub 2023 Jan 11.
6
Post-COVID-19 human memory impairment: A PRISMA-based systematic review of evidence from brain imaging studies.新冠后人类记忆障碍：基于PRISMA的脑成像研究证据系统评价
Front Aging Neurosci. 2022 Dec 9;14:1077384. doi: 10.3389/fnagi.2022.1077384. eCollection 2022.
7
Anti-high mobility group box protein 1 monoclonal antibody downregulating P-glycoprotein as novel epilepsy therapeutics.抗高迁移率族蛋白1单克隆抗体下调P-糖蛋白作为新型癫痫治疗药物
Egypt J Neurol Psychiatr Neurosurg. 2022;58(1):121. doi: 10.1186/s41983-022-00557-8. Epub 2022 Oct 22.
8
Current evidence on the impact of the COVID-19 pandemic on paediatric endocrine conditions.关于 COVID-19 大流行对儿科内分泌疾病影响的现有证据。
Front Endocrinol (Lausanne). 2022 Aug 5;13:913334. doi: 10.3389/fendo.2022.913334. eCollection 2022.
9
Genetic alterations, RNA expression profiling and DNA methylation of HMGB1 in malignancies.HMGB1 基因改变、RNA 表达谱和 DNA 甲基化与恶性肿瘤。
J Cell Mol Med. 2022 Aug;26(15):4322-4332. doi: 10.1111/jcmm.17454. Epub 2022 Jun 28.
10
HMGB1: A Potential Target of Nervus Vagus Stimulation in Pediatric SARS-CoV-2-Induced ALI/ARDS.高迁移率族蛋白B1：小儿严重急性呼吸综合征冠状病毒2诱导的急性肺损伤/急性呼吸窘迫综合征中迷走神经刺激的潜在靶点
Front Pediatr. 2022 May 11;10:884539. doi: 10.3389/fped.2022.884539. eCollection 2022.
本文引用的文献
1
Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease.致编辑的信：肥胖作为代谢相关脂肪性肝病患者感染 COVID-19 时病情更严重的风险因素。
Metabolism. 2020 Jul;108:154244. doi: 10.1016/j.metabol.2020.154244. Epub 2020 Apr 19.
2
Obesity Is a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms.肥胖是重症 COVID-19 感染的危险因素：多种潜在机制。
Circulation. 2020 Jul 7;142(1):4-6. doi: 10.1161/CIRCULATIONAHA.120.047659. Epub 2020 Apr 22.
3
High-resolution Chest CT Features and Clinical Characteristics of Patients Infected with COVID-19 in Jiangsu, China.中国江苏 COVID-19 感染患者的高分辨率胸部 CT 特征和临床特征。
Int J Infect Dis. 2020 Jun;95:106-112. doi: 10.1016/j.ijid.2020.04.003. Epub 2020 Apr 6.
4
Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19.新型冠状病毒肺炎患者的凝血障碍与抗磷脂抗体
N Engl J Med. 2020 Apr 23;382(17):e38. doi: 10.1056/NEJMc2007575. Epub 2020 Apr 8.
5
Elexacaftor-Tezacaftor-Ivacaftor: The First Triple-Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapy.依列卡福妥-替扎卡福妥-依伐卡托：首个三联组合型囊性纤维化跨膜传导调节因子调控疗法
J Pediatr Pharmacol Ther. 2020;25(3):192-197. doi: 10.5863/1551-6776-25.3.192.
6
Emerging Cystic Fibrosis Transmembrane Conductance Regulator Modulators as New Drugs for Cystic Fibrosis: A Portrait of Pharmacology and Clinical Translation.新型囊性纤维化跨膜传导调节因子调节剂作为囊性纤维化的新药：药理学与临床转化概述
ACS Pharmacol Transl Sci. 2019 Oct 2;3(1):4-10. doi: 10.1021/acsptsci.9b00060. eCollection 2020 Feb 14.
7
Diabetes is a risk factor for the progression and prognosis of COVID-19.糖尿病是新冠病毒疾病（COVID-19）进展和预后的一个风险因素。
Diabetes Metab Res Rev. 2020 Oct;36(7):e3319. doi: 10.1002/dmrr.3319. Epub 2020 Apr 7.
8
Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19.靶向内吞途径和自噬过程作为 COVID-19 的一种新治疗策略。
Int J Biol Sci. 2020 Mar 15;16(10):1724-1731. doi: 10.7150/ijbs.45498. eCollection 2020.
9
COVID-19 infection and rheumatoid arthritis: Faraway, so close!COVID-19 感染与类风湿关节炎：远在天边，近在咫尺！
Autoimmun Rev. 2020 May;19(5):102523. doi: 10.1016/j.autrev.2020.102523. Epub 2020 Mar 20.
10
Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis.新型冠状病毒肺炎的临床、实验室和影像学特征：系统评价和荟萃分析。
Travel Med Infect Dis. 2020 Mar-Apr;34:101623. doi: 10.1016/j.tmaid.2020.101623. Epub 2020 Mar 13.
Zotero 插件